Temasek Holdings (Private) Ltd is a multinational investment company that has its headquarters in Singapore. Its investment portfolio includes financial services, telecommunications, media and technology, transportation and industrials, and several others. The company’s SEC 13F Filings for the period ended September 30, 2014, was filed on November 14, 2014. According to the filings, the company’s top three holdings are Level 3 Communications, Inc. (NYSE:LVLT), Alibaba Group Holding Ltd (NYSE:BABA), and Gilead Sciences, Inc. (NASDAQ:GILD).
Level 3 Communications, Inc. (NYSE:LVLT) came out as the topmost investment of Temasek Holdings (Private) Ltd, accounting for $2.5 billion. Level 3 Communications, Inc. (NYSE:LVLT) is a telecommunications company based in Broomfield, Colorado, building, protecting and managing high security networks for enterprises. The stock was recently upgraded to “buy” by Citigroup due to what they say is a high potential for growth occasioned by its increased focus on enterprise.
Alibaba Group Holding Ltd (NYSE:BABA) emerged second on the list with investment worth $1.6 billion. Alibaba Group Holding Ltd (NYSE:BABA) is a Chinese entity that operates as a holding company, providing internet infrastructure, e-commerce, online financial, and internet content services through several of its subsidiaries that serve the global market. According to third quarter SEC 13F filings, the company has attracted several hedge funds to its side, pulling the who-is-who in the investment world. The purchases followed the company’s IPO, which became the world’s biggest ever. The top three shareholders of Alibaba Group Holding Ltd (NYSE:BABA) are Fidelity Management & Research Company, T. Rowe Price Associates, Inc., and Viking Global Investors LP.
Gilead Sciences, Inc. (NASDAQ:GILD) was investment of Temasek Holdings (Private) Ltd with investment totaling $1.4 billion in value. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, manufactures, and sells therapies for viral and infectious diseases as well as cancer. The company made news recently with the release of a once-a-day pill for Hepatitis C. The drug has had impressive results in all tests, going as far as receiving FDA approval. Gilead Sciences, Inc. (NASDAQ:GILD) has been able to register 35% growth every year for the past 5 years, something not common with many companies.
This article has been written by Victor Ochieng.